Several mutations and polymorphisms have beenidentified in PPARγ, such as Lys319X (truncating) and Gln286Pro, insporadic colon cancer, which are associated with loss of DNA-binding andligand-dependent transcription by the PPARγ agonist, troglitazone [13]. Here, PPARG is linked to malignant colon neoplasm.